<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633084</url>
  </required_header>
  <id_info>
    <org_study_id>RBM-007-001</org_study_id>
    <nct_id>NCT03633084</nct_id>
  </id_info>
  <brief_title>RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration</brief_title>
  <acronym>SUSHI</acronym>
  <official_title>Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ribomic USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ribomic USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, non-controlled, dose-escalating study assessing the safety,&#xD;
      tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in&#xD;
      approximately nine subjects with exudative age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nine subjects in three dose cohorts (3 subjects each cohort) will receive a single i.vt.&#xD;
      injection of RBM-007 in the study eye. Subjects will be followed through Day 56.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label, non-controlled, sequential, dose-escalating study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability</measure>
    <time_frame>Day 56</time_frame>
    <description>Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Safety as Assessed Using Ophthalmoscopy to Investigate Ocular Tolerability</measure>
    <time_frame>Day 56</time_frame>
    <description>Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Tolerability as Assessed by Number and Nature of Adverse Events</measure>
    <time_frame>Day 56</time_frame>
    <description>Adverse events (ocular or non-ocular)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>RBM-007 Injectable Solution - 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No additional information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBM-007 Injectable Solution - 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No additional information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBM-007 Injectable Solution - 2.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No additional information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBM-007 Injectable Solution</intervention_name>
    <description>(No additional description)</description>
    <arm_group_label>RBM-007 Injectable Solution - 0.2 mg</arm_group_label>
    <arm_group_label>RBM-007 Injectable Solution - 1.0 mg</arm_group_label>
    <arm_group_label>RBM-007 Injectable Solution - 2.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 55 years of age or older on the date of signing the informed consent&#xD;
             form and able and willing to comply with all treatment and follow-up study procedures.&#xD;
&#xD;
          2. At Screening Visit, subjects must meet all the following inclusion criteria:&#xD;
&#xD;
          3. Must have had prior treatment in the study eye with any intravitreal vasoactive&#xD;
             endothelial growth factor (VEGF) medication (at least 3 anti-VEGF) treatments within&#xD;
             the prior 2-6 months), throughout which clinical examination and SD-OCT imaging has&#xD;
             shown recurrent or persistent exudative activity, as shown by the presence of&#xD;
             intraretinal or subretinal fluid, and/or subretinal exudation or hemorrhage.&#xD;
&#xD;
          4. Best corrected visual acuity of 65 to 20 Early Treatment of Diabetic Retinopathy Study&#xD;
             (ETDRS) letters (20/50 to 20/400) in the study eye.&#xD;
&#xD;
          5. Presence of significant subretinal fluid and/or cystoid macular edema secondary to&#xD;
             exudative age-related macular degeneration as assessed by optical coherence tomography&#xD;
             in the study eye, with a minimum of 300 µm within the central subfield.&#xD;
&#xD;
          6. Total lesion size of ≤9 disc areas, lesion containing ≤50% hemorrhage and ≤50%&#xD;
             subretinal fibrosis and ≤50% retinal pigment epithelial atrophy in the study eye.&#xD;
&#xD;
          7. Reasonably clear media and reasonable fixation ability in the study eye to allow for&#xD;
             good quality tomography and fundus photography.&#xD;
&#xD;
             At Baseline Visit (Day 0), subjects must meet all the following inclusion criteria:&#xD;
&#xD;
          8. Best Corrected Visual Acuity (BCVA) of 65 to 20 ETDRS letters (20/50 to 20/400) in the&#xD;
             study eye.&#xD;
&#xD;
          9. Presence of significant subretinal and/or intraretinal fluid secondary to exudative&#xD;
             age-related macular degeneration as assessed by SD-OCT in the study eye, with a&#xD;
             minimum of 300 µm within the central subfield.&#xD;
&#xD;
         10. Total lesion size of ≤9 disc areas, containing ≤ 50% hemorrhage and ≤ 50% fibrosis and&#xD;
             ≤ 50% retinal pigment epithelial atrophy in the study eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ocular exclusion criteria:&#xD;
&#xD;
          1. BCVA better than 65 ETDRS letters (20/50) in the study eye.&#xD;
&#xD;
          2. BCVA worse than 20 ETDRS letters (20/400) in study eye.&#xD;
&#xD;
          3. Fellow eye BCVA worse than 35 ETDRS letters (20/200).&#xD;
&#xD;
             Use of any of the following treatments to the study eye:&#xD;
&#xD;
          4. Intravitreal anti-VEGF injection (ranibizumab, aflibercept or bevacizumab) in the&#xD;
             study eye within the past 4 weeks or less prior to Baseline Visit and RBM-007&#xD;
             injection.&#xD;
&#xD;
          5. Intravitreal or periocular corticosteroid, within 3 months prior to Baseline Visit&#xD;
             (Day 0) and throughout the study;&#xD;
&#xD;
          6. Fluocinolone acetonide intravitreal implant, within 12 months prior to Baseline Visit&#xD;
             (Day 0) and throughout the study;&#xD;
&#xD;
          7. Visudyne® (verteporfin) photodynamic therapy, within 3 months prior to Baseline Visit&#xD;
             (Day 0) and throughout the study.&#xD;
&#xD;
          8. Uncontrolled or advanced glaucoma, defined by an intraocular pressure (IOP) of &gt;21&#xD;
             mmHg or cup/disc ratio &gt; 0.8 while on medical therapy, or chronic ocular hypotony (&lt;6&#xD;
             mmHg) in the study eye.&#xD;
&#xD;
          9. Evidence of ocular disease other than exudative AMD in the study eye that may confound&#xD;
             the outcome of the study (e.g., active diabetic retinopathy, posterior uveitis, adult&#xD;
             vitelliform dystrophy, moderate/severe myopic degeneration).&#xD;
&#xD;
         10. History of vitrectomy surgery in the study eye.&#xD;
&#xD;
         11. Anticipated need for any ocular surgery involving the study eye during the course of&#xD;
             the study.&#xD;
&#xD;
         12. Nd:YAG laser capsulotomy within 28 days prior to Baseline Visit (Day 0) in the study&#xD;
             eye.&#xD;
&#xD;
         13. Intraocular surgery, including lens removal or ophthalmologic laser procedure, within&#xD;
             90 days prior to Baseline Visit (Day 0) in the study eye.&#xD;
&#xD;
         14. Ocular or periocular infection in either eye.&#xD;
&#xD;
         15. Pupillary dilation inadequate for good quality fundus photography in the study eye.&#xD;
&#xD;
         16. Media opacity that would limit clinical visualization, fundus photography, fluorescein&#xD;
             angiography, or SD-OCT evaluation in the study eye.&#xD;
&#xD;
         17. History of herpetic ophthalmic infection in the study eye or adnexa.&#xD;
&#xD;
         18. Presence of known toxoplasmosis or toxoplasmosis scar in either eye.&#xD;
&#xD;
         19. Presence or history of any form of ocular malignancy including choroidal melanoma in&#xD;
             the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Ali, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ribomic USA Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03633084/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RBM-007 Injectable Solution - 0.2 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="P2">
          <title>RBM-007 Injectable Solution - 1.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="P3">
          <title>RBM-007 Injectable Solution - 2.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RBM-007 Injectable Solution - 0.2 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="B2">
          <title>RBM-007 Injectable Solution - 1.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="B3">
          <title>RBM-007 Injectable Solution - 2.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87" lower_limit="71" upper_limit="88"/>
                    <measurement group_id="B2" value="80" lower_limit="80" upper_limit="85"/>
                    <measurement group_id="B3" value="86" lower_limit="86" upper_limit="92"/>
                    <measurement group_id="B4" value="86" lower_limit="71" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular safety as assessed using biomicroscopy to investigate ocular tolerability</title>
          <description>Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening. By definition, there are zero findings at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular safety as assessed using ophthalmoscopy to investigate ocular tolerability</title>
          <description>Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening. By definition, there are zero findings at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability</title>
        <description>Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RBM-007 Injectable Solution - 0.2 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O2">
            <title>RBM-007 Injectable Solution - 1.0 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O3">
            <title>RBM-007 Injectable Solution - 2.0 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability</title>
          <description>Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Safety as Assessed Using Ophthalmoscopy to Investigate Ocular Tolerability</title>
        <description>Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RBM-007 Injectable Solution - 0.2 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O2">
            <title>RBM-007 Injectable Solution - 1.0 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O3">
            <title>RBM-007 Injectable Solution - 2.0 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Safety as Assessed Using Ophthalmoscopy to Investigate Ocular Tolerability</title>
          <description>Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Tolerability as Assessed by Number and Nature of Adverse Events</title>
        <description>Adverse events (ocular or non-ocular)</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RBM-007 Injectable Solution - 0.2 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O2">
            <title>RBM-007 Injectable Solution - 1.0 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
          <group group_id="O3">
            <title>RBM-007 Injectable Solution - 2 mg</title>
            <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Tolerability as Assessed by Number and Nature of Adverse Events</title>
          <description>Adverse events (ocular or non-ocular)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RBM-007 Injectable Solution - 0.2 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="E2">
          <title>RBM-007 Injectable Solution - 1.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
        <group group_id="E3">
          <title>RBM-007 Injectable Solution - 2.0 mg</title>
          <description>No additional information.&#xD;
RBM-007 Injectable Solution: (No additional description)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Subconjunctival Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mild local irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall, leg injury, and sequelae</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yusuf Ali, Ph.D.</name_or_title>
      <organization>Ribomic USA</organization>
      <phone>(707) 287-4313</phone>
      <email>yusuf.ali@ribomic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

